|
Aug 7
|
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
|
|
Aug 5
|
VALNEVA Declaration of shares and voting rights: July 31, 2025
|
|
Jul 29
|
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
|
|
Jul 24
|
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
|
|
Jul 24
|
High Growth Tech Stocks In Europe With Promising Potential
|
|
Jul 11
|
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
|
|
Jul 11
|
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update
|
|
May 7
|
VALNEVA Declaration of shares and voting rights: April 30, 2025
|
|
May 7
|
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
|
|
May 7
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Mar 10
|
High Growth Tech Stocks In Europe For March 2025
|
|
Feb 18
|
Valneva hits 2024 sales target but plans lower cash burn in 2025
|
|
Feb 18
|
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
|
|
Feb 17
|
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
|
|
Jan 3
|
VALNEVA Declaration of shares and voting rights: December 31, 2024
|